NCT07197892 Conversational AI Platform for Early Pregnancy Care City-wide Recruitment: A Feasibility Study
| NCT ID | NCT07197892 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Pennsylvania |
| Condition | Early Pregnancy |
| Study Type | INTERVENTIONAL |
| Enrollment | 2,637 participants |
| Start Date | 2026-04-06 |
| Primary Completion | 2027-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 2,637 participants in total. It began in 2026-04-06 with a primary completion date of 2027-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study seeks to determine pregnant patients in the Philadelphia area can be recruited to a conversational AI texting platform. The trial will be considered feasible if recruitment goals are met in proportion to delivery volume at the hospital.
Eligibility Criteria
Inclusion Criteria: * Willing and able to provide informed consent * Access to a working mobile phone * Ability to read English * Pregnant with a gestational age less than 12 weeks, 6 days by last menstrual period or by ultrasound, or per patient self-report Exclusion Criteria: N/A
Contact & Investigator
Alice Abernathy
PRINCIPAL INVESTIGATOR
University of Pennsylvania
Frequently Asked Questions
Who can join the NCT07197892 clinical trial?
This trial is open to female participants only, aged 15 Years or older, studying Early Pregnancy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07197892 currently recruiting?
Yes, NCT07197892 is actively recruiting participants. Contact the research team at arden.mcallister@pennmedicine.upenn.edu for enrollment information.
Where is the NCT07197892 trial being conducted?
This trial is being conducted at Philadelphia, United States.
Who is sponsoring the NCT07197892 clinical trial?
NCT07197892 is sponsored by University of Pennsylvania. The principal investigator is Alice Abernathy at University of Pennsylvania. The trial plans to enroll 2,637 participants.